Boston Scientific Corporation vs Global E Online Ltd — how do they compare? Boston Scientific Corporation trades at $43.3 (market cap $66.37B), while Global E Online Ltd trades at $39.73 (market cap $6.51B). The key difference: Boston Scientific Corporation is far larger — about 10.2× Global E Online Ltd's market cap, and Global E Online Ltd is trading nearer its 52-week high, Boston Scientific Corporation nearer its low. Which is the better fit depends on your goals.
| BSX | GLBE | |
|---|---|---|
Market Cap | $66.37B | $6.51B |
Sector | Health | Technology |
52-Week High | $108.14 | $41.59 |
52-Week Low | $42.63 | $27.54 |
Enterprise Value | $75.94B | $5.98B |
Signals from Pluang's Aura AI — not financial advice
Boston Scientific (BSX) trades at $44.65, down 0.27% with bearish technical signals despite strong fundamentals. The company delivered three consecutive earnings beats with Q3-Q1 2026 EPS exceeding expectations, while revenue grew to $20.07B in 2025 with improving profit margins. Technical indicators show bearish momentum with support at $44 and resistance at $45, though Wall Street maintains 88% buy rating with $70.20 consensus target.
BSX presents a compelling value opportunity with attractive valuation multiples (P/E 18.68, P/S 3.24) and robust financial health, though near-term headwinds include competitive pressures in key segments and recent stock price decline of nearly 60% from 2025 highs. The strong analyst consensus suggests significant upside potential if execution improves.
GLBE trades at $38.68, up 0.52% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported strong Q1 2026 results with revenue growth of 33% year-over-year and raised full-year guidance, achieving a 'Rule of 50' metric. Recent acquisition of Passport enhances logistics capabilities, supporting future growth. Valuation remains elevated with a P/E of 57.84 and P/S of 6.7, reflecting high growth expectations.
Outlook is positive driven by robust merchant demand and cross-border expansion, though risks include execution of acquisitions and competitive pressures. Analysts are unanimously bullish with a $38 consensus target, near the current price. Stock investors should monitor earnings consistency and integration success for sustained upside.
Trailing returns across standard periods
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Read more on BSX →Global-e provides a platform for cross-border e-commerce, helping retailers increase international sales by localizing the shopping experience for consumers in over 200 destinations worldwide.
Read more on GLBE →